Tag Archives: NASDAQ:IRWD

H.C. Wainwright Sticks to Its Hold Rating for Ironwood Pharma (IRWD)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Ironwood Pharma (IRWD – Research Report), with a price target of $13. The company’s shares closed on Friday at $10.95. Selvaraju wrote: “We utilize a

Ironwood Pharma (IRWD) Gets a Hold Rating from Barclays

Barclays analyst Geoff Meacham maintained a Hold rating on Ironwood Pharma (IRWD – Research Report) on May 2 and set a price target of $13. The company’s shares closed on Friday at $10.61. According to TipRanks.com, Meacham is a 4-star

Mizuho Securities Reiterates Their Buy Rating on Ironwood Pharma (IRWD)

In a report released today, Irina Rivkind Koffler from Mizuho Securities reiterated a Buy rating on Ironwood Pharma (IRWD – Research Report), with a price target of $20. The company’s shares closed yesterday at $11.78. Rivkind Koffler commented: “We reiterate

Ironwood Pharma (IRWD) Receives a Hold from H.C. Wainwright

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Ironwood Pharma (IRWD – Research Report), with a price target of $14. The company’s shares closed on Friday at $11.48. Selvaraju noted: “We utilize a

The CLO of Ironwood Pharma is Exercising Options

Today it was reported that the CLO of Ironwood Pharma (IRWD – Research Report), Halley Gilbert, exercised options to buy 20,449 IRWD shares at $4.89 a share, for a total transaction value of $100K. The options were close to expired

Cowen & Co. Sticks to Its Hold Rating for Ironwood Pharma (IRWD)

Cowen & Co. analyst Boris Peaker maintained a Hold rating on Ironwood Pharma (IRWD – Research Report) today and set a price target of $16. The company’s shares opened today at $12.90. According to TipRanks.com, Peaker is a 4-star analyst